You are here

Articles

Brian Druker: My Vision for CML and the Road to a Cure

published: 21 August 2012

Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

published: 16 August 2012

New Data Confirm Safety of Stopping Imatinib in CML

published: 30 July 2012

ARIAD Announces Initiation of Randomized Phase 3 Trial of Ponatinib in Newly Diagnosed CML

published: 30 July 2012

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

published: 6 July 2012

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

published: 3 July 2012

EHA 2012: Conference

published: 3 July 2012

Imatinib Mesylate Discontinuation in Patients With CML Treated with Front-Line IM Therapy and Achieved Complete Molecular Response

published: 25 June 2012

ASCO 2012:

published: 11 June 2012

The expanding options for front-line treatment in patients with newly diagnosed CML

published: 26 May 2012

Minimal Residual Disease

published: 10 May 2012

My Approach to Chronic Myeloid Leukemia Interview by L Scott Zoeller. 2012 Apr 3, Tim Hughes, MD

published: 3 May 2012

Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia

published: 3 May 2012

The CMLSg will not appeal the NICE FAD which refuses recommendation of dasatinib for first line use in CML.

published: 15 April 2012

Welcome to cmlsupport.org.uk

published: 29 March 2012

CMLSg's comment on FAD: 1st line use of dasatinib, nilotinib, imatinib. CMLSg will not appeal this FAD.

published: 23 March 2012

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

published: 10 March 2012

Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis

published: 7 March 2012

Chronic Myeloid Leukaemia Treatment in Evolution

published: 22 February 2012

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

published: 5 February 2012